Pure Biologics S.A. (FRA:PQB)

Pure Biologics Cash Flow Statement

Financials in millions PLN. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-17.93	-19.44	-35.69	-25.6	-11.77	-11.76
Depreciation & Amortization	0.28	0.31	0.21	2.23	2.65	3.07
Other Amortization	-	-	-	0.27	0.27	0.04
Loss (Gain) From Sale of Assets	-0.69	-	0.24	0.62	0.03	-
Other Operating Activities	4.01	1.34	8.65	4.76	3.01	3.95
Change in Accounts Receivable	7.06	12.98	0.2	-5.93	-7.94	-0.34
Change in Inventory	-	-	-	-	-	0.09
Change in Unearned Revenue	-	-4.81	1.95	-0.93	-8.59	4.2
Change in Other Net Operating Assets	3.53	-0.9	-6.65	7.19	-1.71	-0.61
Operating Cash Flow	-5.12	-10.83	-23.26	-17.39	-24.04	-1.35
Capital Expenditures	-	-	-0.18	-5.76	-0.67	-0.56
Sale of Property, Plant & Equipment	3.87	3.87	4.93	0.05	0.01	-
Investment in Securities	-	-	-4	21.05	-27.81	-
Other Investing Activities	-3.63	-0.31	-0.37	-	-	-
Investing Cash Flow	0.24	3.56	0.39	15.35	-28.48	-0.56
Long-Term Debt Issued	-	4.42	12	-	-	-
Total Debt Issued	4.42	4.42	12	-	-	-
Long-Term Debt Repaid	-	-0.15	-6.64	-1.55	-2.15	-2.7
Total Debt Repaid	-0.09	-0.15	-6.64	-1.55	-2.15	-2.7
Net Debt Issued (Repaid)	4.33	4.27	5.36	-1.55	-2.15	-2.7
Issuance of Common Stock	-	-	18.86	-	52.11	-
Other Financing Activities	0.29	-0.29	-	-0.33	-0.23	-0.35
Financing Cash Flow	3.71	3.98	24.22	-1.88	49.74	-3.05
Miscellaneous Cash Flow Adjustments	0	-	-0	-	-	-
Net Cash Flow	-1.17	-3.29	1.35	-3.92	-2.78	-4.97
Free Cash Flow	-5.12	-10.83	-23.44	-23.15	-24.71	-1.91
Free Cash Flow Margin	-	-	-	-3496.22%	-9727.56%	-334.62%
Free Cash Flow Per Share	-1.29	-3.11	-7.35	-10.27	-11.12	-1.16
Cash Interest Paid	0.02	0.07	-	0.33	0.23	0.35
Levered Free Cash Flow	3.77	1.43	-10.05	-14.08	-19.85	2.22
Unlevered Free Cash Flow	4.97	2.26	-9.51	-13.88	-19.71	2.44
Change in Working Capital	10.59	7.27	-4.5	0.33	-18.24	3.34

Source: S&P Global Market Intelligence. Standard template. Financial Sources.